Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR4A2 | P43354 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 3/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.47 |
| ▸ | MEN1 | O00255 | 5/20 | 0.47 |
| ▸ | BRCA1 | P38398 | 1/20 | 0.47 |
| ▸ | STAT3 | P40763 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.46 |
| ▸ | POLB | P06746 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.43 |
| ▸ | CDK9 | P50750 | 1/20 | 0.43 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.42 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | USP2 | O75604 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | ATM | Q13315 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7292220 | 0.82 | ALDH1A1 (0.66) | MAPTKMT2AMEN1STAT3ALDH1A1 | |
| SCHEMBL665932 | 0.77 | MEN1 (0.56) | NR4A2MAPTKMT2AMEN1BRCA1 | |
| SCHEMBL10654844 | 0.76 | CYP19A1 (0.56) | NR4A2MAPTKMT2AMEN1BRCA1 | |
| SCHEMBL6210692 | 0.76 | IMPDH2 (0.67) | NR4A2MAPTKMT2AMEN1ALDH1A1 | |
| SCHEMBL6802017 | 0.74 | ALDH1A1 (0.55) | MAPTKMT2AMEN1ALDH1A1SMN1; SMN2 | |
| SCHEMBL6800938 | 0.73 | SLC22A12 (0.50) | MAPTKMT2AMEN1STAT3ALDH1A1 | |
| SCHEMBL10396791 | 0.73 | NR4A2 (0.51) | NR4A2MAPTKMT2AMEN1BRCA1 | |
| SCHEMBL13806314 | 0.72 | NR4A2 (0.50) | NR4A2MAPTKMT2AMEN1BRCA1 | |
| SCHEMBL3621031 | 0.72 | NR4A2 (0.50) | NR4A2MAPTKMT2AMEN1BRCA1 | |
| SCHEMBL3262677 | 0.72 | NR4A2 (0.54) | NR4A2MAPTKMT2AMEN1BRCA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6656963-B2 | Inhibits tumor cell growth | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2003-12-02 | — | — | US | disclosed |
| US-20030087946-A1 | Indole-3-carbinol (I3C) derivatives and methods | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2003-05-08 | — | — | US | disclosed |
| US-6369095-B1 | ANTITUMOR | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2002-04-09 | — | — | US | disclosed |
| WO-2001030344-A1 | INDOLE-3-CARBINOL (I3C) DERIVATIVES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2001-05-03 | — | — | WO | disclosed |
| US-6150395-A | CYCLIN DEPENDENT KINASE (CDK) INHIBITORS INHIBIT THE GROWTH OF ESTROGEN-DEPENDENT OR INDEPENDENT BREAST CANCER CELLS AND OTHER TYPES OF CANCER CELLS THAT REVEAL INDUCED CDK6; ANTIESTROGENS; ANTITUMOR AGENTS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2000-11-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030087946-A1 | Indole-3-carbinol (I3C) derivatives and methods | CDK6, CDK3, CDKL3 | NR4A2 1748/4885MAPT 4188/4885KMT2A 1309/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.